Trade agreement may restrict supply of essential drugs in Central America, experts sayBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7512.310-e (Published 04 August 2005) Cite this as: BMJ 2005;331:310
- John Zarocostas
Health and development advocacy groups fear that stringent intellectual property provisions imposed by the United States in a new free trade pact will trigger higher prices of drugs and will restrict access to cheap essential generic drugs, including antiretrovirals, in poor Central American nations.
The Central American free trade agreement between and the US and Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, and Nicaragua was approved by the US House of Representatives on 27 July by a vote of 217 to 215.
The pact has many aspects that are problematic and will raise drug prices and strengthen the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial